Article

As a range of drugmakers rush to approvals for their COVID-19 vaccine, big-money supply deals and logistical hurdles have left developing nations concerned about access to potential winners. In few places is that concern larger than in India, the second most populous nation on Earth, and a vaccines giant has stepped into ensure its home country will get those shots. 

As part of massive pacts with British drugmaker AstraZeneca and a coalition of global nonprofits, the Serum Institute of India (SII) will create access to more than 1 billion doses of licensed COVID-19 vaccines to low- and middle-income countries, including in India itself. 

In late September, SII pledged to make an additional 100 million COVID shot doses available in 2021 as part of an expanded distribution effort with Gavi, the Vaccines Alliance, and the Bill & Melinda Gates Foundation.  As part of their ramped-up manufacturing pact, the Gates Foundation will plug an additional $150 million into boosting SII and Gavi’s production capacity to provide shots at a maximum of $3 per dose, bringing its total commitment to $300 million. 

SII’s expanded pledge will bring the partnership’s total commitment to 200 million doses in 2021. Distribution would begin in the first half of the year, provided at least one of its licensed shots—from AstraZeneca and Novavax—passes muster with regulators.

The institute has previously stated its goal to produce up to 1 billion doses per year to low- and middle-income countries. In order to hit that stout pledge—one of the largest commitments of any vaccine maker in the race—SII reportedly pursued a $1 billion cash raise back in August to help boost manufacturing. 

Back in June, AstraZeneca tapped SII in a licensing deal to provide 1 billion doses of its adenovirus-based COVID-19 shot to low- and middle-income countries, with the goal of 400 million produced by year’s end. That licensing pact came at the same time AstraZeneca signed a $750 million supply deal with CEPI and Gavi for its shot, dubbed AZD1222. 

Sours:- https://www.fiercepharma.com/special-report/top-10-manufacturers-fight-against-covid-19

While the world has changed for everyone—and drugmakers expect some financial pain this year—many enjoyed a productive year last year, with sales increases, new drug launches, M&A deals and plenty of clinical data. Those companies, and some with less stellar résumés, rewarded their CEOs handsomely for that work.

Here the list of Top paid CEOs of 2019

(1) Martine Rothblatt

Martine Rothblatt, United Therapeutics 
2019 total pay: $45.64 million 
2018 total pay: $16.01 
Percentage change: 185% 

(2) Daniel O’Day

Daniel O’Day, Gilead Sciences
2019 pay: $29.11 million
2018 pay: N/A
Change: N/A

(3) Kenneth Frazier

Kenneth Frazier, Merck & Co.
2019 pay: $27.65 million
2018 pay: $20.93 million
Change: 32%

(4) Alex Gorsky

Alex Gorsky, Johnson & Johnson
2019 total pay: $25.37 million
2018 total pay: $20.1 million 
Percentage change: 26.2%

(5) Richard Gonzalez

Richard Gonzalez, AbbVie
2019 total pay: $21.61 million
2018 total pay: $21.28 million
Percentage change: 1.6%

Full Article:- https://www.fiercepharma.com/special-report/top-15-highest-paid-biopharma-ceos-2019

Find out top 10 company by 2026 sales. Propelled by new rollouts in oncology, multiple sclerosis and hemophilia, Roche is set to lead all Big Pharma companies in 2026 sales, according to consensus forecasts from EvaluatePharma. With nearly $62 billion in expected drug sales that year, analysts believe the drugmaker will easily beat the second-place company, Pfizer, with its expected $56.1 billion.

Behind Pfizer, Johnson & Johnson, Novartis, AbbVie and Merck & Co. are all set to pull in more than $50 billion in 2026 drug sales, the analysts predict. Besides the launches already in the works and pipeline candidates advancing when 2020 began, they’ve all joined the hunt for COVID-19 drugs and vaccines.

Here is the chart of 10 Global Company by actual 2019 and by projected 2026.

Ranking	By projected 2026 drug sales	By actual 2019 drug sales
1	Roche	Roche
2	Pfizer	Pfizer
3	Johnson & Johnson	Novartis
4	Novartis	Johnson & Johnson
5	AbbVie	Merck & Co.
6	Merck & Co.	Sanofi
7	Sanofi	GlaxoSmithKline
8	GlaxoSmithKline	AbbVie
9	Bristol Myers Squibb	Takeda
10	AstraZeneca	Bristol Myers Squibb

Source:- https://www.fiercepharma.com/special-report/top-15-pharma-companies-by-2026-sales

As we all know, how challenging it is to do a job as a Medical Representative in the time of Covid-19. Not all companies have paid salary to MR in Covid-19 (lockdown) and have paid only half salary to some. Too many MR jobs are not safe right now. As we all know, in this age of technology and online, our future is not secure.

Therefore, we have to know a lot in the timing of this Covid-19. You should not be dependent on a single job. We need to think about the sources of part-time income that can give us even a small amount of income in such a difficult time.

So today I want to say that we have to continue this job with confidence and raise a source of income so that work can be done in times of crisis. Today I would like to give information about the source of income that we can get part time income without giving more time and leaving the current job.

Income Source 1: –

Amazon Store: – Nowadays it is time for online. Most people will be shopping online today. The prevalence of online is bound to increase day by day. Anyone can create their own store on Amazon and sell the product. I believe that this option is the best option for us. I also have my own store in Amazon. And I also get side income.

How to open a store in Amazon

(1) Company Formation (GST number) (Rs. 1500)

(2) Bank Current Account (for Co-operative) (Rs. 2000)

(2) Printer (Rs. 2000)

(2) Computer or mobile

For less than Rs 10,000, your Amazon store is up and running.

After opening the store, you can sell any product you like. You can also do this part time. If you are married, your wife can also support you in this. And the other benefit is that you can do this business side by side with your job.

Source of income – 2

Facebook Instant Article: –

We all do the job of spending most of the day on mobile. So Facebook Instant Article is a tool from where you can earn a few times income by writing an article online. The funny thing is that you don’t have to invest in this.

How to start a Facebook instant article: –

(1) Blogger is a Gmail tool where you can write and post your articles. Blogger account can be opened for free.

(2) To activate Facebook Instant Article, it is necessary to write a minimum of 10 articles in Blogger.

(3) Have to create your own page on Facebook.

(2) After creating the page, you have to apply for the Facebook Instant Article.

All this can be activated for free. In my opinion, these two sources of income can be very useful in the current standard of living if they are implemented with a positive attitude now.

Thanks for reading the article. And if you want more information you can email [email protected].

If you like my article please share it.

Many pharma companies have contributed to the PM Care Fund during the Covid-19 epidemic. In addition some company donates N-95 masks, testing kits, food packets, meals, medicines, etc.

Pharma companies have contributed to the PM Care Fund as follows.

(1) Torrent Pharma Group donates 100 crore in PM care fund.

(2) Jubilant Bhatia Group Donate 10 crore in PM Care Fund.

(3) Cipla donate 25 crore in PM care fund.

(4) Piramal Pharma donate 25 crore in PM care fund.

(5) Lupine donate 21 crore in PM care fund.

(6) Alchem ​​donate 7 crore in PM care fund.\

(7) Ajanta Pharma donate 2 crore in PM care fund.

In addition, all the companies have also contributed to the CM Care Fund. As Himachal Pradesh Pharma’s manufacturing hub, the state has raised more funds. Apart from this, funds have also been raised in Gujarat, Karnataka, Andhra Pradesh, Maharashtra, Odisha and other states.